UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)
XOANACYL is an oral therapy designed to address critical challenges in CKD,…
Semilux Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 20-F
June 02, 2025 19:30 ET Â | Source: Semilux International Ltd. Taipei, Taiwan,…